Neuroendocrine carcinomas: Optimal surgery of peritoneal metastases (and associated intra-abdominal metastases)

Élias, Dominique; David, Anaëlle; Sourrouille, Isabelle; Honoré, Charles; Goèré, Diane; Dumont, Frédéric; Stoclin, Annabelle; Baudin, Éric

doi:10.1016/j.surg.2013.05.030

Cited by 63 publications

(55 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same group of authors has recently updated their series [31]. Among 41 patients with PC derived from NET of various origins (76% small intestinal), 28 underwent complete CRS + HIPEC and 13 complete CRS alone, with similar 2-year survival rates (81 vs. 73%, respectively).…”

Section: Results Of the Surgical Treatment Of Pc In Netmentioning

confidence: 99%

“…Finally, HIPEC appears to be less beneficial for patients with peritoneal metastases associated with NET than for those with colorectal cancer. Indeed, the 5-year PC relapse rate after CRS + HIPEC was about 33% for patients with colorectal cancer [32,33] but reached 55% for NET patients [31]. …”

Section: Results Of the Surgical Treatment Of Pc In Netmentioning

confidence: 99%

“…Cytotoxic agents used, alone or combined, include platin salts, irinotecan, mitomycin C, 5-fluorouracil and doxorubicin. At the end of the procedure, the perfusate is drained and the abdomen is irrigated with normal saline [10,15,31]. …”

Section: Modalities Of the Surgical Treatment Of Pcmentioning

confidence: 99%

“…Extended liver resection, e.g. right hepatectomy, simultaneously with CRS and HIPEC for PC, could cause more morbidity, while minor liver resections and/or ablative treatments could be combined [10,31]. …”

Section: Modalities Of the Surgical Treatment Of Pcmentioning

confidence: 99%

See 3 more Smart Citations

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Mestier¹,

Lardière-Deguelte

Brixi³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Well-differentiated digestive neuroendocrine tumors (NET) are a heterogeneous group of neoplasms usually associated with slow growth but a high rate of metastases, including peritoneal carcinomatosis (PC). Herein, we aimed to comprehensively review the current knowledge of PC in terms of implications for the management and prognosis of patients with NET, including the latest studies and expert statements. NET-derived PC concerns about 17% of NET patients and up to 30% of those with small intestine primary NET. It has an independent pejorative prognostic impact. The extent of PC in NET patients and its severity can be expressed by analogy to other malignancies. However, it must be placed in the context of NET disorders, which usually vary from other PC-related malignancies. Recently, a gravity PC score was proposed by a consensus European Neuroendocrine Tumor Society (ENETS) expert group, but it requires validation. In addition, the form of peritoneal involvement (nodular or fusiform/infiltrative) might influence its prognosis and management. Aggressive surgical management seems justified for subsets of NET-related PC but requires careful selection of the candidates most likely to benefit. Cytoreductive surgery prolongs survival, especially when the peritoneal lesions are completely resected. Too little is known about the benefit of hyperthermic intraperitoneal chemotherapy for NET-derived PC, but if it confers an advantage, it would have to be counterbalanced by its high morbidity.

show abstract

Section: Results Of the Surgical Treatment Of Pc In Netmentioning

confidence: 99%

Section: Results Of the Surgical Treatment Of Pc In Netmentioning

confidence: 99%

Section: Modalities Of the Surgical Treatment Of Pcmentioning

confidence: 99%

Section: Modalities Of the Surgical Treatment Of Pcmentioning

confidence: 99%

See 2 more Smart Citations

Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Mestier¹,

Lardière-Deguelte

Brixi³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…HIPEC is applied after an extended surgical intervention including macroscopic disease, excision of the peritoneum, omentum, ovaries, uterine etc. The main limitation of HIPEC in this setting is that chemotherapy is used against tumors with a low proliferative rate (85). Added risk of morbidity and mortality should be also taken into consideration when HIPEC is considered simultaneously with another major surgery (81).…”

Section: Diffuse Peritoneal Carcinomatosis (Pc)mentioning

confidence: 99%